A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

What Was Tested

The trial (phase 2) is built around Semaglutide.

It had three arms (groups): zovaglutide Arm1 (experimental), zovaglutide Arm2 (experimental) and semaglutide Arm (active comparator).

Participants will receive semaglutide once weekly after randomization.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 210 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female subjects aged≥18years and≤75 years at the time of signing the Informed Consent Form (ICF). At screening, Body Mass Index (BMI)≥28kg/m².

The full record lists 3 inclusion and 8 exclusion criteria; among the exclusions: previously diagnosed obesity caused by monogenic mutations, other diseases, or medications; used of medicines or treatments that affect weight within 3 months prior to screening; history of acute or chronic pancreatitis, or pancreatic injury.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

The Semaglutide group and the comparison group ran side by side rather than switching.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2026-10-12 with completion listed for 2028-01-13.

It ran at 16 sites in China (16).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Proportion of participants achieving successful switch from semaglutide [amount hidden] to zovaglutide after randomization.

It also tracked 5 secondary outcomes, for example Proportion of participants achieving successful switch without severe gastrointestinal adverse event (GIAE), Incidence of GIAE, Percentage of GIAE-free duration relative to total period after randomization and Changes in body weight from randomization.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 210 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.